Myeloproliferative Neoplasm (MPN)NCT07590986
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
An observational study of Myeloproliferative Neoplasm (MPN) and Polycytemia Vera, run by Université Catholique de Louvain at 1 site in Belgium.
Trial summary
The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Myeloproliferative Neoplasm (MPN), Polycytemia Vera, Essential Thrombocythemia (ET)
- How many people
- 150 participants
- Where
- 1 siteBelgium
- Study dates
- May 2026to Jan 2037
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: (i) Adult patients previously diagnosed with or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN. (ii) Healthy controls undergoing hip replacement surgery, that have not been diagnosed with any hematological disease.
Who may be able to join
- Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN.
- Patients not previously diagnosed with a haematological disease as controls
Who cannot join
- Patients with any other hematological malignancy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
de Duve Institute, UCLouvain
Brussels, Woluwe, 1200
Sophie Lucas, Pr, 0032 (0)2 436 23 00, sophie.lucas@uclouvain.be
Violaine Havelange
About this study
The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN.
The main questions it aims to answer are:
Read more
- Are there T cells in the bone marrow that can recognize MPN cells?
- Which targets (antigens) on MPN cells are recognized by these immune cells?
- Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies?
Researchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison.
By providing blood and bone marrow samples, participants will:
- Allow researchers to study immune cells and genetic material from these samples
- Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells
Researchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN.
Participants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.
- Conditions
- Myeloproliferative Neoplasm (MPN), Polycytemia Vera, Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF)
- Medical subject headings
- Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Identification of MPN-specific CD8+ T cell clonotypes and corresponding tumor antigens
Measured: Throughout the whole study, approximately during 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2026
- Study startMay 2026 (estimated)
- Primary completionDec 2036 (estimated)
- Study completionJan 2037 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myeloproliferative Neoplasm (MPN)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07590986
- Sponsor's protocol ID
- MPN-TCR
- Status last verified
- May 2026
- First submitted
- 8 May 2026
- Last updated
- 15 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No